This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Waites, K. B.
Right arrow Articles by Duffy, L. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Waites, K. B.
Right arrow Articles by Duffy, L. B.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2005, p. 2541-2542, Vol. 49, No. 6
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.6.2541-2542.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Comparative In Vitro Activities of Investigational Peptide Deformylase Inhibitor NVP LBM-415 and Other Agents against Human Mycoplasmas and Ureaplasmas

Ken B. Waites,* Nipun B. Reddy, Donna M. Crabb, and Lynn B. Duffy

Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama 35249

Received 10 December 2004/ Returned for modification 27 January 2005/ Accepted 31 January 2005


arrow
ABSTRACT
 
Peptide deformylase inhibitor LBM-415 and seven other drugs were tested against Mycoplasma pneumoniae (100 isolates), Mycoplasma hominis (20 isolates), Mycoplasma fermentans (10 isolates), and Ureaplasma species (50 isolates). LBM-415 was active against M. pneumoniae (MICs, ≤0.008 µg/ml). It showed no activity against M. hominis and M. fermentans and modest activity against Ureaplasma spp.


arrow
TEXT
 
NVP LBM-415 (formerly PDF-713) is an investigational peptide deformylase (PDF) inhibitor that has in vitro activity against major respiratory tract pathogens, including Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis (1, 9). This drug also has activity against many other gram-positive bacterial pathogens, including staphylococci and enterococci (4, 9).

Mycoplasma pneumoniae is a significant cause of upper and lower respiratory tract infections in persons of all age groups (13, 14). Mycoplasma hominis and Ureaplasma species are associated with a variety of conditions involving the urogenital tract and sometimes cause extragenital infections in adults and infants, especially in immunocompromised hosts of all ages (13). Mycoplasma fermentans may also behave as an opportunistic pathogen in some settings (13). Antimicrobial treatment, usually rendered empirically, is often necessary to treat infections due to these organisms. We performed the present study to evaluate the in vitro inhibitory and bactericidal activities of NVP LBM-415 against clinical isolates of human mycoplasmas and ureaplasmas in comparison to antimicrobial agents that are known to have in vitro activity against these organisms.

The microorganisms tested included the following: 100 M. pneumoniae isolates collected from a broad geographic area over a 10-year period from the respiratory tract of individuals with proven respiratory disease; 10 M. fermentans isolates from the mycoplasma collection at the National Institutes of Health; 20 M. hominis isolates derived from clinical specimens of the urogenital tract or wound cultures; and 50 Ureaplasma isolates, including both U. urealyticum and U. parvum derived from adult urogenital or neonatal respiratory cultures. Drugs tested in addition to LBM-415 included azithromycin, clarithromycin, doxycycline, levofloxacin, gatifloxacin, moxifloxacin, and clindamycin. Clindamycin was tested only against M. hominis and M. fermentans because it is not recommended for treatment of M. pneumoniae (3) and has no activity against Ureaplasma spp. (13). Azithromycin and clarithromycin were tested only against M. pneumoniae and Ureaplasma spp. since M. hominis is always resistant to macrolides and M. fermentans is frequently resistant to these agents as well (5, 13). For the determination of MICs, antimicrobial powders were dissolved and diluted according to the manufacturers' instructions on the day of assay. Serial twofold dilutions of drugs were made in 10 B broth for Ureaplasma and SP4 broth for Mycoplasma spp. (13). MICs were then determined as described previously (12). Five M. pneumoniae and two Ureaplasma isolates were randomly chosen for further testing to determine minimal bactericidal concentrations. Time-kill assays were also performed on these same M. pneumoniae isolates, using procedures described previously (12).

A summary of MICs obtained is shown in Table 1. NVP LBM-415 demonstrated excellent in vitro activity against all 100 isolates of M. pneumoniae. All isolates were inhibited by LBM-415 at ≤0.008 µg/ml, and the MIC90 (0.001 µg/ml) was the lowest of any drug tested except azithromycin. There was also activity in vitro against ureaplasmas, with MICs ranging from 0.5 to 8.0 µg/ml, but LBM-415 was the least potent agent tested against these organisms in terms of MIC50 and MIC90. One Ureaplasma isolate was resistant to doxycycline (MIC = 8 µg/ml), and its corresponding MIC for LBM-415 was 4 µg/ml. LBM-415 had no appreciable activity in vitro against M. hominis or M. fermentans, as evidenced by all MICs for these mycoplasmas exceeding 32 µg/ml, with most of them exceeding 256 µg/ml.


View this table:
[in this window]
[in a new window]
  		TABLE 1. MIC summary for LBM-415 tested against mycoplasmas and ureaplasmas

NVP LBM-415 activity against M. pneumoniae and Ureaplasma species was bacteriostatic. Minimal bactericidal concentrations for this agent were ≥8 times the corresponding MIC for both Ureaplasma isolates and all five M. pneumoniae isolates tested. Bacteriostatic effect was also evident by the time-kill assay. This observation is consistent with what has been reported for this drug against other bacterial pathogens such as Staphylococcus aureus and Escherichia coli (2, 4).

Even though genes encoding PDF have been identified in all eubacterial human pathogens for which the entire genomic sequence is known, recent evidence suggests that peptide deformylation is not essential under all circumstances in every eubacterial species (11). PDF genes have been described in M. pneumoniae, Mycoplasma genitalium, and Ureaplasma spp. (7, 8), but some mycoplasmas of animal origin such as Mycoplasma hyopneumoniae do not encode the gene for PDF (10). Whether the lack of inhibitory activity of NVP LBM-415 against M. fermentans and M. hominis is due to a lack of PDF in these species, whether it may be present but nonessential, or whether an alternative mechanism of resistance is operative is not known, since their complete genomic content has not been determined. It should be noted that M. hyopneumoniae is a member of the M. hominis taxonomic group within the class Mollicutes, as is M. fermentans (15). Since these organisms are somewhat closely related, it is plausible that none of them encodes the gene for PDF.

Our MIC data indicated that M. pneumoniae is susceptible to LBM-415 at very low concentrations rivaling those of the macrolides, which are known to be the most potent drugs against this organism. However, its inhibition of Ureaplasma spp. was considerably less. Whether these higher MICs for Ureaplasma spp. were a direct result of less potent inhibition or possibly other factors, such as the effect of the medium composition and low pH (pH 6.0) necessary to cultivate ureaplasmas in vitro, is not known.

NVP LBM-415 is an interesting agent that merits further study for potential use in treatment of respiratory tract infections caused by M. pneumoniae and other bacterial pathogens for which it has known inhibitory properties. Resistance mechanisms in peptide deformylase inhibitors have been described, so it is important to consider the potential impact of this in their clinical developments (6).


arrow
ACKNOWLEDGMENTS
 
This work was supported by a grant from Novartis Pharmaceuticals, East Hanover, N.J.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Department of Pathology, WP 230, 619 19th Street South, Birmingham, AL 35249. Phone: (205) 934-4960. Fax: (205) 975-4468. E-mail: waites{at}path.uab.edu. Back


arrow
REFERENCES
 
    1
  1. Anderegg, T. R., and R. N. Jones. 2004. Disk diffusion quality control guidelines for NVP-PDF 713: a novel peptide deformylase inhibitor. Diagn. Microbiol. Infect. Dis. 48:55-57.[CrossRef][Medline]
    2. 2
  2. Apfel, C. M., H. Locher, S. Evers, B. Takács, C. Hubschwerlen, W. Pirson, M. G. Page, and W. Keck. 2001. Peptide deformylase as an antibacterial drug target: target validation and resistance development. Antimicrob. Agents Chemother. 45:1058-1064.[Abstract/Free Full Text]
    3. 3
  3. Clyde, W. A., Jr. 1979. Mycoplasma pneumoniae infections of man, p. 275-306. In J. G. Tully and R. F. Whitcomb (ed.), The mycoplasmas II. Human and animal mycoplasmas, vol. II. Academic Press, New York, N.Y.
    4. 4
  4. Credito, K., G. Lin, L. M. Ednie, and P. C. Appelbaum. 2004. Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents. Antimicrob. Agents Chemother. 48:4033-4036.[Abstract/Free Full Text]
    5. 5
  5. Duffy, L. B., D. Crabb, K. Searcey, and M. C. Kempf. 2000. Comparative potency of gemifloxacin, new quinolones, macrolides, tetracycline and clindamycin against Mycoplasma spp. J. Antimicrob. Chemother. 45(Suppl. 1):29-33.[Abstract]
    6. 6
  6. Giglione, C., and T. Meinnel. 2001. Resistance to anti-peptide deformylase drugs. Expert Opin. Ther. Targets 5:415-418.[CrossRef][Medline]
    7. 7
  7. Giglione, C., M. Pierre, and T. Meinnel. 2000. Peptide deformylase as a target for new generation, broad spectrum antimicrobial agents. Mol. Microbiol. 36:1197-1205.[CrossRef][Medline]
    8. 8
  8. Glass, J. I., E. J. Lefkowitz, J. S. Glass, C. R. Heiner, E. Y. Chen, and G. H. Cassell. 2000. The complete sequence of the mucosal pathogen Ureaplasma urealyticum. Nature 407:757-762.[CrossRef][Medline]
    9. 9
  9. Jones, R. N., G. J. Moet, H. S. Sader, and T. R. Fritsche. 2004. Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates. J. Antimicrob. Chemother. 53:804-807.[Abstract/Free Full Text]
    10. 10
  10. Minion, F. C., E. J. Lefkowitz, M. L. Madsen, B. J. Cleary, S. M. Swartzell, and G. G. Mahairas. 2004. The genome sequence of Mycoplasma hyopneumoniae strain 232, the agent of swine mycoplasmosis. J. Bacteriol. 186:7123-7133.[Abstract/Free Full Text]
    11. 11
  11. Newton, D. T., C. Creuzenet, and D. Mangroo. 1999. Formylation is not essential for initiation of protein synthesis in all eubacteria. J. Biol. Chem. 274:22143-22146.[Abstract/Free Full Text]
    12. 12
  12. Waites, K. B., D. M. Crabb, X. Bing, and L. B. Duffy. 2003. In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas. Antimicrob. Agents Chemother. 47:161-165.[Abstract/Free Full Text]
    13. 13
  13. Waites, K. B., Y. Rikihisa, and D. Taylor-Robinson. 2003. Mycoplasma and Ureaplasma, p. 972-990. In P. R. Murray, E. J. Baron, J. H. Jorgensen, M. A. Pfaller, and R. H. Yolken (ed.), Manual of clinical microbiology, 8th ed. ASM Press, Washington, D.C.
    14. 14
  14. Waites, K. B., and D. F. Talkington. 2004. Mycoplasma pneumoniae and its role as a human pathogen. Clin. Microbiol. Rev. 17:697-728.[Abstract/Free Full Text]
    15. 15
  15. Weisburg, W. G., J. G. Tully, D. L. Rose, J. P. Petzel, H. Oyaizu, D. Yang, L. Mandelco, J. Sechrest, T. G. Lawrence, J. Van Etten, J. Maniloff, and C. R. Woese. 1989. A phylogenetic analysis of the mycoplasmas: basis for their classification. J. Bacteriol. 171:6455-6467.[Abstract/Free Full Text]

Antimicrobial Agents and Chemotherapy, June 2005, p. 2541-2542, Vol. 49, No. 6
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.6.2541-2542.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Bogdanovich, T., Smith, K. A., Clark, C., Pankuch, G. A., Lin, G., McGhee, P., Dewasse, B., Appelbaum, P. C. (2006). Activity of LBM415 Compared to Those of 11 Other Agents against Haemophilus Species.. Antimicrob. Agents Chemother. 50: 2323-2329 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Waites, K. B.
Right arrow Articles by Duffy, L. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Waites, K. B.
Right arrow Articles by Duffy, L. B.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»